- Home
- PRHI vs QNRX Comparison
PRHI vs QNRX Comparison
Compare PRHI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRHI | QNRX |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | 9 | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 11.6M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | PRHI | QNRX |
|---|---|---|
| Price | $5.25 | $4.65 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.5K | 25.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $4.55 |
| 52 Week High | $2.83 | $41.80 |
Technical Indicators
Market Signals| Indicator | PRHI | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 95.42 | 30.64 |
| Support Level | $0.60 | $4.55 |
| Resistance Level | N/A | $6.84 |
| Average True Range (ATR) | 0.12 | 0.43 |
| MACD | 0.31 | -0.04 |
| Stochastic Oscillator | 100.00 | 3.11 |
Price Performance
Historical ComparisonAbout PRHI Presurance Holdings Inc.
Presurance Holdings Inc Formerly Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.